SMAD2 and familial pancreatic carcinoma: To further address the prognostic implications of the identified genomic alterations, we performed gene-specific survival analyses for mutations that showed significant differences in frequency between Hispanic/Latino (H/L) and Non-Hispanic White (NHW) pancreatic cancer patients, including SMAD2, SMAD4, CTNNB1, ERBB4, and ALK.